BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+3.95%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$9.45B
AUM Growth
+$9.45B
(+8.2%)
Cap. Flow
+$607M
Cap. Flow
% of AUM
6.42%
Top 10 Holdings %
Top 10 Hldgs %
29.09%
Holding
237
New
15
Increased
96
Reduced
78
Closed
21
Top Buys
| 1 |
ACCD
Accolade, Inc. Common Stock
ACCD
|
$53.3M |
| 2 |
ESSA Pharma
EPIX
|
$53M |
| 3 |
Revolution Medicines
RVMD
|
$47.1M |
| 4 |
SILK
Silk Road Medical, Inc. Common Stock
SILK
|
$39.8M |
| 5 |
Becton Dickinson
BDX
|
$32.4M |
Top Sells
| 1 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
$100M |
| 2 |
Halozyme
HALO
|
$43.1M |
| 3 |
GNMK
GenMark Diagnostics, Inc
GNMK
|
$38.1M |
| 4 |
CHNG
Change Healthcare Inc. Common Stock
CHNG
|
$33.3M |
| 5 |
Esperion Therapeutics
ESPR
|
$32.2M |
Sector Composition
| 1 | Healthcare | 95.93% |
| 2 | Industrials | 0.88% |
| 3 | Technology | 0.47% |
| 4 | Consumer Discretionary | 0.04% |
| 5 | Financials | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ionis Pharmaceuticals
IONS
$6.79B
| $404M | 4.27% | 8,984,234 -65,858 | -0.7% | -$2.96M |
|
2
Moderna
MRNA
$9.37B
| $368M | 3.89% | 2,809,950 -136,963 | -5% | -$17.9M |
|
3
Neurocrine Biosciences
NBIX
$13.8B
| $318M | 3.37% | 3,274,551 -122,100 | -4% | -$11.9M |
|
4
Vertex Pharmaceuticals
VRTX
$100B
| $296M | 3.13% | 1,376,704 +137,719 | +11% | +$29.6M |
|
5
argenx
ARGX
$43.6B
| $263M | 2.78% | 954,554 +9,206 | +1% | +$2.54M |
|
6
Incyte
INCY
$16.5B
| $244M | 2.58% | 3,005,700 -3,000 | -0.1% | -$244K |
|
7
Agios Pharmaceuticals
AGIO
$2.19B
| $234M | 2.48% | 4,537,092 +336,090 | +8% | +$17.4M |
|
8
Alnylam Pharmaceuticals
ALNY
$58.5B
| $230M | 2.43% | 1,627,114 +23,614 | +1% | +$3.33M |
|
|
ALXN
9
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $200M | 2.12% | 1,308,728 -84,300 | -6% | -$12.9M |
|
10
MacroGenics
MGNX
$112M
| $192M | 2.03% | 6,027,926 +123,409 | +2% | +$3.93M |
|
11
Fate Therapeutics
FATE
$120M
| $182M | 1.93% | 2,209,336 +101,836 | +5% | +$8.4M |
|
12
Abbott
ABT
$231B
| $167M | 1.77% | 1,392,999 -3,874 | -0.3% | -$464K |
|
13
Intuitive Surgical
ISRG
$170B
| $163M | 1.73% | 220,775 +24,755 | +13% | +$18.3M |
|
|
RDUS
14
DELISTED
Radius Health, Inc.
RDUS
| $157M | 1.66% | 7,531,414 | – | – |
|
15
Biogen
BIIB
$19.4B
| $156M | 1.65% | 558,400 -5,600 | -1% | -$1.57M |
|
16
Elevance Health
ELV
$71.8B
| $138M | 1.46% | 385,548 +49,755 | +15% | +$17.9M |
|
17
Arvinas
ARVN
$568M
| $137M | 1.45% | 2,071,503 -120,000 | -5% | -$7.93M |
|
|
SAGE
18
DELISTED
Sage Therapeutics
SAGE
| $136M | 1.43% | 1,810,704 +243,200 | +16% | +$18.2M |
|
19
UnitedHealth
UNH
$281B
| $133M | 1.41% | 357,381 +51,336 | +17% | +$19.1M |
|
20
Bristol-Myers Squibb
BMY
$96B
| $132M | 1.39% | 2,085,152 +280,680 | +16% | +$17.7M |
|
|
21
Halozyme
HALO
$8.56B
| $126M | 1.33% | 3,011,966 -1,033,034 | -26% | -$43.1M |
|
|
ITCI
22
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $124M | 1.31% | 3,659,919 | – | – |
|
23
Humana
HUM
$36.5B
| $121M | 1.28% | 288,719 +51,652 | +22% | +$21.7M |
|
24
CRISPR Therapeutics
CRSP
$4.71B
| $119M | 1.26% | 978,384 +68,700 | +8% | +$8.37M |
|
25
Insulet
PODD
$23.9B
| $113M | 1.2% | 434,188 +96,720 | +29% | +$25.2M |
|